MedPath

GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse

Completed
Conditions
Pelvic Organ Prolapse
Interventions
Device: GYNECARE PROSIMA* Pelvic Floor Repair System
Registration Number
NCT00521066
Lead Sponsor
Ethicon, Inc.
Brief Summary

The purpose of this study is to is to evaluate the success of the GYNECARE PROSIMA\* system in women with symptoms for pelvic organ prolapse (POP) requiring surgical correction of POP.

(\*TRADEMARK)

Detailed Description

The GYNECARE PROSIMA\* system provides a simplified mesh repair, avoiding the need for dissection outside the pelvic cavity.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
150
Inclusion Criteria
  • Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III, suitable for surgical repair. Vaginal hysterectomy, perineal repair and/or mid urethral sling procedures for incontinence may be performed concurrently.
  • Age ≥ 18 years.
  • Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.
Exclusion Criteria
  • Additional surgical intervention concurrent to the PROSIMA procedure (e.g. sacrocolpopexy, paravaginal repair, tubal sterilisation).
  • Previous repair of pelvic organ prolapse involving insertion of mesh.
  • Previous hysterectomy within 6 months of scheduled surgery.
  • Experimental drug or experimental medical device within 3 months prior to the planned procedure.
  • Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
  • Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
  • History of chemotherapy or pelvic radiation therapy.
  • Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
  • Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
  • Nursing or pregnant or intends future pregnancy.
  • In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1GYNECARE PROSIMA* Pelvic Floor Repair SystemProsima Pelvic Floor Repair System
Primary Outcome Measures
NameTimeMethod
Success based on overall POP-Q score at 12 months post-procedure.12-months

Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP.

Secondary Outcome Measures
NameTimeMethod
Mean change from baseline in PISQ-12 score24 months

In subjects sexually active at baseline, assessment of sexual function

Success based on treated compartment ICS POP-Q stage24 months

Success will be determined by achievement of treated compartment POP-Q score of ICS Stage ≤1, without further re-intervention for POP.

Mean PFDI-20 score24 months
Mean change from baseline in PFDI-20 scores12 months
Mean change from baseline in POPDI score24 months

POPDI is a sub score of PFDI-20

Mean change from baseline in CRADI score24 months

CRADI is a sub score of PFDI-20

Mean CRAIQ score24 months

CRAIQ is a sub-score of PFIQ-7

Mean PISQ-12 score24 months

In subjects sexually active at baseline, assessment of sexual function

Mean POPIQ score24 months

POPIQ is a sub-score of PFIQ-7

Mean change from baseline in UIQ score24 months

UIQ is a sub-score of PFIQ-7

Discomfort of balloon removal, measured using VAS at time of removal.24 hrs post-surgical
Subject perception of VSD: Awareness3-4 week visit

Measured by visual analogue scale

Success based on overall POP-Q score at 24 months post-procedure.24 months

Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP

Success defined as the leading edge within the hymen24 months

Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)

EuroQol (EQ-5D health state) change from baseline24 months
Mean change from baseline in CRAIQ score24 months

CRAIQ is a sub-score of PFIQ-7

Mean UIQ score24 months

UIQ is a sub-score of PFIQ-7

Mean POPDI score24 months

POPDI is a sub score of PFDI-20

Mean UDI score24 months

UDI is a sub score of PFDI-20

Mean change from baseline in UDI score24 months

UDI is a sub score of PFDI-20

Mean PFIQ-7 score24 months
Mean change from baseline in PFIQ-7 score24 months
Subject perception of VSD: Discomfort3-4 week visit

Measured by visual analogue scale

Mean CRADI score24 months

CRADI is a sub score of PFDI-20

Mean change from baseline in POPIQ score24 months

POPIQ is a sub-score of PFIQ-7

Pain score measured using Visual Analog Scale (VAS).24 hours post surgery and at the 3-4 week visit
Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareuniaongoing
Length of procedureperioperative

From time to first incision to time of last suture used to secure VSD

Subject perception of VSD: Acceptability of discharge3-4 week visit

Measured by visual analogue scale

Subject global impression24 month visit

assessed on a 5 point Likert scale

Trial Locations

Locations (11)

Female Pelvic Medicine and Urogynecology Institute of Michigan

🇺🇸

Dearborn, Michigan, United States

Specialists in Urology

🇺🇸

Naples, Florida, United States

Universitatsklinik Tubingen

🇩🇪

Tubingen, Germany

Female Pelvic Medicine & Urogynecology

🇺🇸

Grand Rapids, Michigan, United States

St. Mary's Hospital

🇬🇧

Manchester, United Kingdom

Magee Women's Hospital of the Universtiy of Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

The Institute for Female Pelvic Medicine & Reconstructive Surgery

🇺🇸

Allentown, Pennsylvania, United States

Royal Women's Hospital

🇦🇺

Melbourne, Australia

Addenbrookes Hospital

🇬🇧

Cambridge, United Kingdom

Bereich Urogynakologie

🇩🇪

Halle, Germany

North Hampshire Hospital

🇬🇧

Hampshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath